<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Techne Corporation
________________________________________________________________________________
(Name of Issuer)
Common Stock, $.01 par value
________________________________________________________________________________
(Title of Class of Securities)
0008783771
_______________________________________________________________
(CUSIP Number)
George A. Vandeman
One Amgen Center Drive,
Thousand Oaks, California 91320-1789
________________________________________________________________________________
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
April 15, 1998
_______________________________________________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
Check the following box if a fee is being paid with the statement [_]. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
- ----------------------- ---------------------
CUSIP NO. 0008783771 PAGE __ OF __ PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
AMGEN INC.
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS*
4
NA
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
DELAWARE
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0 shares
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
0 shares
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 0 shares
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
0 shares
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
0 shares
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
12
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
0%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
PRELIMINARY NOTE
This Amendment No. 1 amends the Schedule 13D filed by Amgen Inc. dated
July 23, 1992 (the "Schedule"). This Amendment No. 1 is being filed because
Amgen Inc. is no longer subject to the reporting requirements of Section
13(d) of the Security Exchange Act of 1934 as a result of the disposition of
the 1,071,894 shares of common stock ($.01 par value) of Techne Corporation (the
"Issuer") previously held by Amgen Inc. (the "Shares") pursuant to a sale of the
Shares on the open market on April 15, 1998 for $17.00 per share.
Other than as set forth below, to the best knowledge of Amgen Inc., there has
been no material change in the information set forth in response to Items 1, 3,
6 and 7 of the Schedule. Accordingly, these Items are omitted from this
Amendment No. 1.
Item 2.
- ------
1. (a) Reporting Person: Amgen Inc. ("Amgen")
(b) Place of Organization: Delaware
(c) Principal Business: Pharmaceuticals
Principal Business Address:
Amgen Inc.
Amgen Center
One Amgen Center Drive
Thousand Oaks, Ca 91320-1789
Principal Office: (See above address)
(d) See 2(d) and (e) below
2. (a) Enumerated Persons:
The executive officers and directors of Amgen are as follows:
Name Position Held with Amgen
---- ------------------------
Mr. Gordon M. Binder Chairman of the Board;
Chief Executive Officer
Mr. Kevin W. Sharer President, Chief Operating
Officer, member of the Board
<PAGE>
Dr. N. Kirby Alton Senior Vice President -
Development
Mr. Robert S. Attiyeh Senior Vice President - Finance and
Corporate Development
Mr. Stanley M. Benson Senior Vice President - Sales and
Marketing
Dr. Dennis M. Fenton Senior Vice President - Operations
Mr. Edward F. Garnett Vice President - Human Resources
Mr. Daryl D. Hill Senior Vice President - Quality
and Compliance
Dr. George Morstyn Vice President, Clinical
Development and Chief Medical
Officer
Mr. Steven M. Odre Vice President - Intellectual Property
and Associate General Counsel
Dr. Lawrence M. Souza Senior Vice President - Research
Mr. George A. Vandeman Senior Vice President - General
Counsel and Secretary
Mr. William K. Bowes, Jr. Director
Mr. Frederick W. Gluck Director
Mr. Franklin P. Johnson, Jr. Director
Mr. Steven Lazarus Director
Mr. Edward J. Ledder Director
Dr. Gilbert S. Omenn Director
Ms. Judith C. Pelham Director
<PAGE>
(b) Business address:
The business address of the above named individuals are as follows:
Binder, Sharer, Alton, Attiyeh, Amgen Inc.
Benson, Fenton, Garnett, Hill, Amgen Center
Morstyn, Odre, Souza and One Amgen Center Drive
Vandeman Thousand Oaks, CA 91320
Mr. Bowes U.S. Venture Partners
2180 Sand Hill Road, Suite 300
Menlo Park, California 94025
Mr. Gluck Bechtel Group Inc.
50 Beale Street
San Francisco, California 94105
Mr. Johnson Asset Management Partners
2275 East Bayshore Road
Suite 150
Palo Alto, California 94303
Mr. Lazarus ARCH Venture Partners, L.P.
O'Hare Plaza
8735 W. Higgins Road
Suite 235
Chicago, Illinois 60631
Mr. Ledder Medicine Bow River Ranch
P. O. Box 410
Medicine Bow, Wyoming 82329
Dr. Omenn University of Michigan
Health System
1301 Catherine Drive
Room M7324
Ann Arbor, Michigan 48109
Ms. Pelham Mercy Health Services
34605 Twelve Mile Road
Farmington Hills, Michigan 48331
<PAGE>
(c) Principal Employment, Name of Employer, Principal Business:
Binder, Sharer, Alton, Attiyeh, Benson, Fenton, Garnett, Hill,
Morstyn, Odre, Souza and Vandeman are employed by Amgen in the
capacities named above.
Mr. Bowes is a general partner of U.S. Venture Partners, a venture
capital investment entity, whose address is given above.
Mr. Gluck is retired Vice Chairman of Bechtel Group, Inc. whose
address is given above.
Mr. Johnson is a general partner of Asset Management Partners, a
venture capital limited partnership, whose address is given above.
Mr. Lazarus is the managing general partner of ARCH Venture Partners,
L.P., an early stage venture capital partnership, whose address is
given above.
Mr. Ledder is retired. He is the former Chairman and Chief Executive
Officer of Abbott Laboratories, Inc., a human health care products
company.
Dr. Omenn is the Executive Vice President for Medical Affairs for the
University of Michigan Health System, whose address is given above.
Ms. Pelham is President and Chief Executive Officer of Mercy Health
Services, a unified system of institutions, programs and services,
whose address is given above.
(d) & (e) During the last five years, neither Amgen, nor, to the best of
its knowledge, any of its executive officers or directors (i)
has been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors); or (ii) has been a party to
a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceedings was
or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any
violation with respect to such laws.
(f) All of the persons enumerated above are citizens of the United States
of America.
<PAGE>
Item 4.
- ------
NA
Item 5.
- ------
(a) As a result of the disposition of 1,071,894 shares of common stock ($.01
par value) of the Issuer pursuant to the open market sale of such shares on
April 15, 1998, Amgen does not beneficially own any shares of common stock
($.01 par value) of the Issuer.
(b) Amgen does not have the sole power to vote or to direct the vote, shared
power to vote or to direct the vote, sole power to dispose or to direct the
disposition or shared power to dispose or to direct the disposition of
common stock ($.01 par value) of the Issuer.
(c) Other than the transaction described in this Amendment No. 1, there were no
transactions in the common stock ($.01 par value) of the Issuer that were
effected during the past sixty days.
(d) To the best knowledge of Amgen, no person other than Amgen has the right to
receive or the power to direct the receipt of dividends from, or the
proceeds from the sale of the common stock ($.01 par value) of the Issuer
that occurred on April 15, 1998.
(e) Amgen ceased to be the beneficial owner of more than five percent of the
common stock ($.01 par value) of the Issuer on April 15, 1998.
<PAGE>
SIGNATURE PAGE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: April 24, 1998
AMGEN INC.
By: /S/ GEORGE A. VANDEMAN
----------------------------
George A. Vandeman
Senior Vice President, General
Counsel and Secretary
